6 results about "Primary immunization" patented technology

The invention discloses a method for preparing a high-titer polyclonal antibody from a Zika virus strain, which comprises the following steps: selecting the Zika virus strain, culturing in cells, and purifying virus particles with high purity to prepare an immunogen; an optimized animal immunization strategy is adopted and comprises the steps of selecting a proper host animal, applying a potent immunologic adjuvant, namely a Freund's adjuvant, and designing a scientific immunization program, so that humoral immune response of the host is stimulated to the maximum extent; when the titer of the antibody reaches a peak value, collecting antiserum, synthesizing hybridoma cells through splenocytes, and obtaining the high-purity polyclonal antibody through a multi-step purification technology. According to the method, high-purity and non-chemically-inactivated whole virus particles which retain natural conformation are used as immunogens, a mode of primary immunization and multiple booster immunization is adopted, a Freund's adjuvant is combined, animals are continuously stimulated to generate high-titer antibodies, non-specific antibodies and impurities are effectively removed through multi-step purification, and the immunogen immunogen is obtained. The target antibody with high purity and high specificity is obtained.

An aspect provides a vaccine composition for preventing tuberculosis comprising chorismate mutase. The vaccine composition alone may induce immunity specific to Mycobacterium tuberculosis, and when provided together with an immune adjuvant, the vaccine composition may induce immunity specific to tuberculosis more effectively. Furthermore, when an existing vaccine for tuberculosis is used as a prime and the vaccine composition according to an aspect including chorismite mutase is provided as a booster, the immunity specific to tuberculosis may be induced significantly more effectively.

The invention discloses a construction method and application of a toxoplasma gondii RH delta cenl1 attenuated vaccine strain, and belongs to the technical field of vaccine preparation. A CENL1 gene is knocked out from an RH delta ku80 strain through CRISPR / Cas9 mediated gene editing, so that a toxoplasma gondii RH delta cenl1 attenuated vaccine strain is obtained. The attenuated vaccine strain is a toxoplasma gondii live vaccine candidate strain with an attenuated characteristic, shows significantly reduced toxicity in a mouse body, and can induce the body to generate strong immune response mainly including Th1 type. Immune protection evaluation results show that mice surviving after primary immunization of RH delta cenl1 do not show a complete protection effect after being infected again by the high-toxicity RH strain, but the survival time of the immunized mice can be remarkably prolonged, the disease progress can be slowed down, and certain immune protection potential is shown. The invention provides an important experimental basis for screening of toxoplasma gondii attenuated live vaccines and optimization of immune prevention and control strategies.

The invention relates to the technical field of IgY antibodies, in particular to a preparation method and application of an anti-human papilloma virus IgY antibody, and the preparation method comprises the following steps: S1, preparing an immunogen; s2, carrying out stepped immunization; s3, collection and pretreatment of hyper-immune eggs: from 18-25 days after primary immunization, collecting eggs laid by the immunized hens, and after surface disinfection, taking yolk liquid for later use; s4, preliminarily extracting an antibody; s5, preliminarily concentrating and purifying the antibody; s6, fine purification of the antibody; s7, performing preparation treatment on the antibody; according to the present invention, the HPV L1 virus-like particle (VLP) immunogen strategy is adopted, the cross protection potential of the high immunogenicity of the L1 VLP is completely performed, the efficient adjuvant system is matched, the poultry is effectively induced to produce the high titer neutralizing antibody with wide cross reactivity, and the defects of limited single antigen targeting type and narrow protection range are overcome.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody for HPV16 type E7 protein detection and application of the monoclonal antibody. E7 protein serving as an antigen and a Freund's complete adjuvant are mixed, then a mouse is subjected to primary immunization, then the E7 protein and a Freund's incomplete adjuvant are mixed, then the mouse is subjected to enhanced immunization, and the HPV16 type E7 protein detection monoclonal antibody is obtained. The monoclonal antibody for detecting the HPV16 type E7 protein is prepared by taking mouse splenocytes and myeloma cells to be fused to prepare hybridoma cells, then performing clone detection on the hybridoma cells to screen the hybridoma cells aiming at the specificity of the HPV16 type E7 protein, and finally obtaining the monoclonal antibody for detecting the HPV16 type E7 protein. According to the present invention, the HPV16 type E7 antigen detection kit is developed by using the immunochromatography method, and the kit has advantages of high sensitivity, strong specificity, simple operation and fast detection speed, and can be used for rapid screening diagnosis and illness state monitoring of HPV16.

The invention belongs to the technical field of chicken disease prevention, and particularly relates to a quadruple inactivated vaccine for preventing chicken diseases, which is prepared by respectively proliferating four viruses, namely a newcastle disease virus LaSota strain, an infectious bronchitis virus M41 strain, an infectious bursal disease virus BJQ902 strain and a viral arthritis virus T98 strain, on an SPF chicken embryo and a chicken embryo fibroblast to obtain a virus solution, the preparation method comprises the following steps: carrying out 2-4 times concentration, inactivating by using a formaldehyde solution, proportioning according to a certain ratio, emulsifying, preparing an inactivated vaccine, carrying out safety and immune effect tests on the inactivated vaccine by using SPF (specific pathogen free) chickens, carrying out serology and challenge protection tests on the inactivated vaccine, carrying out physical property detection on the prepared inactivated vaccine, and continuously observing for 14 days, according to the present invention, the immune effect test results show that the Newcastle disease antibody level can achieve more than 6.0 log2 after the immunization for 28 d, and the antibody titer after the secondary immunization of the infectious bronchitis is 9 times of the first immunization of the infectious bronchitis;